Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K

As of March 31, 2026, Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K carries a market capitalization of 151.83M, placing it among publicly traded companies globally. Its enterprise value stands at 2.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K has 1.11B shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 0.33, and the price-to-book ratio stands at 0.09.

These figures are as of March 31, 2026. The EV/Sales ratio of 5.22 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.52B versus a market cap of 151.83M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K maintains a current ratio of 0.58, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 134.01, indicating elevated leverage, while an interest coverage ratio of -0.81 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K posted a negative return on equity (ROE) of -19.68, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.36, reflecting losses generated across the asset base. The company generates approximately 944,076.25 in revenue per employee across its workforce of 511.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.62 indicates how many times Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K recorded 277.09M in income tax expense. The company reported a pretax loss of -106.37M and -386.62M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K's stock has declined approximately 45.82% over the past 52 weeks. The 50-day moving average sits at 0.13, while the 200-day moving average is 0.13.

Over the twelve months ended March 31, 2026, Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K generated 482.90M in revenue and converted that into -386.62M in net income, yielding earnings per share of -0.33. EBITDA reached -118.77M, while operating income came in at -241.97M.

As of March 31, 2026, Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K holds 16.57M in cash and equivalents against 2.37B in total debt, resulting in a net debt position of 2.22B. Total book value stands at 1.76B, with working capital of -1.30B providing operational flexibility.

Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K produced 10.19M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -12.86M in capital expenditures, free cash flow totaled -2.67M - equivalent to 0.00 per share.

Over the twelve months ended March 31, 2026, Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K posted a gross margin of -28.62, reflecting its pricing power and cost economics. The operating margin of -50.11 and net profit margin of -80.06 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -1.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 6.16, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K shareholders.

Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K's most recent stock split took place on April 23, 2015.

As of March 31, 2026, Proteak Uno SAB de CV Cert Part Ord Cons of 1 sh T and 2 shs K has an Altman Z-Score of -0.87, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.